ReviewCPT: pharmacometrics & systems pharmacology2018
Many Flavors of Model-Based Meta-Analysis: Part II - Modeling Summary Level Longitudinal Responses.
Review in CPT: pharmacometrics & systems pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma.European journal of clinical pharmacology · 2025Pooled it
- Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.Clinical pharmacokinetics · 2024Pooled it
- Applications of Model-Based Meta-Analysis in Drug Development.Pharmaceutical research · 2022Pooled it
- Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.CPT: pharmacometrics & systems pharmacology · 2022Pooled it
- Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.Frontiers in immunology · 2021Pooled it
- Population Pharmacokinetics of Sertraline in Healthy Subjects: a Model-Based Meta-analysis.The AAPS journal · 2020Pooled it
- A Systematic Review and Meta-Analysis on the Longitudinal Effects of Unilateral Knee Extension Exercise on Muscle Strength.Frontiers in sports and active living · 2020Pooled it
- Predicting the dose of vancomycin in ICU patients receiving different types of RRT therapy: a model-based meta-analytic approach.British journal of clinical pharmacology · 2019Pooled it
- Regimen-stratified Bayesian model-based meta-analysis of targeted biologics in generalised myasthenia gravis: efficacy comparison, mechanism-level class contrast, and endpoint sensitivity with model-informed trial design.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis.CPT: pharmacometrics & systems pharmacology · 2026Article
- Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data.CPT: pharmacometrics & systems pharmacology · 2026Article
- Quantitative Approaches to Accelerate MASH Drug Discovery and Development.Clinical pharmacology and therapeutics · 2025Review
- State-of-the-Art on Model-Informed Drug Development Approaches for Pediatric Rare Diseases.CPT: pharmacometrics & systems pharmacology · 2025Review
- Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meta-analyses typically assess comparative treatment response for an end point at specific timepoints across studies. However, during drug development, it is often of interest to understand the response time-course of competitor compounds for a variety of purposes. Examples of such application include informing study design and characterizing the onset, maintenance, and offset of action. This tutorial acts as a "points for consideration" document, reviews relevant literature, and fits a longitudinal model to an example dataset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.